New Trial Data Show ‘Promising’ Sustained Sutimlimab Effects

New Trial Data Show ‘Promising’ Sustained Sutimlimab Effects

291524

New Trial Data Show ‘Promising’ Sustained Sutimlimab Effects

Sanofi’s investigational therapy sutimlimab safely and rapidly prevents red blood cell destruction (hemolysis), increases hemoglobin levels, and reduces fatigue in adults with primary cold agglutinin disease (CAD), according to full data from Part A of the Phase 3 CARDINAL study. These therapeutic benefits were associated with a fast and pronounced suppression of the classical complement pathway, whose overactivation causes CAD, confirming sutimlimab’s mechanism of action and biological activity. “These pivotal results underscore the clear and clinically…

You must be logged in to read/download the full post.